---
figid: PMC3335938__cbt1212_1032_fig001
figtitle: Key therapeutic targets in the PI3K/Akt and MAPK pathways together with
  pharmacological agents inhibiting members of these signaling cascades
organisms:
- Homo sapiens
- Mus musculus
pmcid: PMC3335938
filename: cbt1212_1032_fig001.jpg
figlink: /pmc/articles/PMC3335938/figure/F1/
number: F1
caption: Schematic representation of key therapeutic targets in the PI3K/Akt and MAPK
  pathways together with pharmacological agents inhibiting members of these signaling
  cascades. Shown are the key therapeutic targets regulating melanoma development.
  Whereas PI3K/Akt3 pathway involved in cell survival and apoptosis regulation, MAPK
  pathway is implicated in cell proliferation. Targeting members of these signaling
  cascades using pharmacological agents has been shown to inhibit melanoma tumor development.
  Pharmacological agents inhibiting PI3K/Akt signaling; perifosine, 17-AAG, CCI-779
  and RAD-001 have been evaluated in clinical trials. Vemurafenib and sorafenib targeting
  MAPK are also being evaluated in various clinical trials for inhibiting melanomas.
papertitle: The Akt signaling pathway.
reftext: SubbaRao V Madhunapantula, et al. Cancer Biol Ther. 2011 Dec 15;12(12):1032-1049.
year: '2011'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9565684
figid_alias: PMC3335938__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC3335938__F1
ndex: 7253af85-dee7-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3335938__cbt1212_1032_fig001.html
  '@type': Dataset
  description: Schematic representation of key therapeutic targets in the PI3K/Akt
    and MAPK pathways together with pharmacological agents inhibiting members of these
    signaling cascades. Shown are the key therapeutic targets regulating melanoma
    development. Whereas PI3K/Akt3 pathway involved in cell survival and apoptosis
    regulation, MAPK pathway is implicated in cell proliferation. Targeting members
    of these signaling cascades using pharmacological agents has been shown to inhibit
    melanoma tumor development. Pharmacological agents inhibiting PI3K/Akt signaling;
    perifosine, 17-AAG, CCI-779 and RAD-001 have been evaluated in clinical trials.
    Vemurafenib and sorafenib targeting MAPK are also being evaluated in various clinical
    trials for inhibiting melanomas.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pten
  - Sh2
  - Myo15a
  - ras
  - Hras
  - Kras
  - Rem1
  - Serpina1c
  - Creb1
  - Psma5
  - Akt3
  - Foxo4
  - Foxo1
  - Zhx2
  - Mdm2
  - Braf
  - Mtor
  - Akt1s1
  - Mdk
  - Trp53
  - Cdkn1b
  - Dctn6
  - Psmd9
  - Wee1
  - Cdkn1a
  - Nsg1
  - Tpt1
  - Tceal1
  - Bad
  - Rps6kb1
  - Ephb2
  - Mapk1
  - Ccnd1
  - Bcl2l1
  - PTEN
  - KRAS
  - HRAS
  - NRAS
  - PI3
  - PDK1
  - PDK2
  - PDK3
  - PDK4
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - CHUK
  - IKBKB
  - IKBKG
  - IKBKE
  - TBK1
  - PSMA5
  - AP5Z1
  - AKT3
  - FOXO4
  - FOXO1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MDM2
  - MTOR
  - AKT1S1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - TP53
  - TP63
  - TP73
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - WEE1
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - BAD
  - RPS6KB1
  - RPS6KB2
  - EPHB2
  - MAPK1
  - MAPK3
  - CCND1
  - BCL2L1
  - Perifosine
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
